Quindoline Anti-HSV Compounds for G-Quadruplex Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating and preventing Herpes Simplex Virus (HSV) infections are inadequate, particularly in addressing viral activity and latency, and there is a need for improved therapies to manage HSV-related conditions.
Innovation Solution
The use of small-molecule compounds with a quindoline structure that stabilize G-quadruplex structures to inhibit HSV activity and expression, offering methods for treating, suppressing, or preventing HSV infections and associated disorders through direct contact with a composition containing these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for treating and preventing HSV infections are used, then existing treatment options are available, but they are inadequate in addressing viral activity and latency
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of quindoline compounds (Formula I) with various substituents (R1-R6 groups) to optimize their ability to stabilize G-quadruplex structures. This structural parameter optimization enhances the compounds' antiviral activity against HSV while maintaining selectivity for viral G4 structures over telomeric sequences, thereby improving treatment effectiveness and addressing both viral activity and latency
2Object-affected harmful factors
If small-molecule compounds with quindoline structure are used to stabilize G-quadruplex structures, then HSV activity and expression are inhibited, but the mechanism requires specific molecular interactions with viral G4 structures
Solution Approach 1:
The patent applies local quality by designing quindoline compounds with specific local structural features (substituent groups at defined positions in Formula I) that confer selective affinity for HSV G-quadruplex structures. This localized structural optimization enables the compounds to preferentially bind and stabilize viral G4 structures over other DNA structures, effectively inhibiting HSV activity through targeted molecular interactions
3Reliability
If compounds are used to treat HSV infection, then therapeutic benefits such as reducing infection frequency and severity are achieved, but the treatment must contact the subject with the composition
Solution Approach 1:
The patent demonstrates universality by showing that the quindoline compounds (Formula I) can be administered through multiple routes (systemic or topical application) to treat various HSV manifestations including oral lesions, genital ulcers, and ocular infections. This multi-functional approach allows a single compound class to address diverse clinical presentations and treatment needs, simplifying the overall treatment strategy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively stabilize G-quadruplex structures, inhibiting HSV activity and expression, providing therapeutic benefits such as reducing infection frequency, severity, and latency, and enhancing susceptibility to additional therapies.
Implementation Method 1
the compounds can be used to treat, ameliorate, or prevent a viral condition that is characterized by resistance to viral therapies... through stabilization of G-quadruplex structures related to viral activity and/or expression
Data Source
AI summary
This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same in a subject comprising the step of contacting the subject with a composition comprising a quindoline (or similar) structure having significant anti-HSV activity.